Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFD Technologies Share News (FDP)

  • This share is currently suspended. It was suspended at a price of 2,450.00
  • There is currently no data for FDP

FD Technologies reports mixed first half

Tue, 26th Nov 2024 14:12

(Sharecast News) - FD Technologies reported mixed half-year results on Tuesday, as revenue from its KX platform grew 5% to £39.5m, helping to offset a 12% decline in revenue from its First Derivative division.

The AIM-traded firm said group revenue declined 7% over the six months ended 31 August, to £118.2m, which it put down to challenging market conditions, particularly in First Derivative.

Adjusted EBITDA fell to £10.5m from £14.2m year-on-year, due to increased investment in KX's growth initiatives.

KX, the group's data analytics and decision-making platform, recorded an 8% increase in annual recurring revenue to £74.6m, or 10% at constant currency.

Annual contract value additions reached £7.4m, within the expected range of £6m to £8m.

Net revenue retention stood at 112% at constant currency.

The group said it was undergoing a significant transformation with the planned divestment of First Derivative for £230m, expected to close on 2 December.

Following the sale, FD Technologies said it would be exclusively focussed on KX as its core business.

From the net divestment proceeds of £205m, £54m would be retained to fund KX's growth, while £120m would be returned to shareholders through a tender offer and potentially a special dividend.

The divestment was aligned with the group's strategy to enhance KX's position as a leading provider of real-time analytics in sectors such as capital markets, aerospace and defense, and semiconductor manufacturing.

FD Technologies said it aimed to accelerate annual recurring revenue growth to about 25% annually, and achieve positive cash EBITDA for KX by the 2027 financial year.

For 2025, the board said it expected KX to add £16m to £18m in ACV and achieve annual recurring revenue growth of 11% to 15%.

"We have made significant strategic and operational progress in the first half, with the divestment of First Derivative and strong execution in KX," said chief executive officer Seamus Keating.

"Following the completion of the sale of First Derivative, we expect to return cash to shareholders, in line with our disciplined approach to capital allocation, and KX will be a pure-play, high-growth software business; fully funded and well-positioned to capitalise on the significant and growing global market opportunity."

At 1352 GMT, shares in FD Technologies were up 8.92% at 1,954p.

Reporting by Josh White for Sharecast.com.

Related News

FD Technologies revenue rises but loss widens as admin costs mount
3 Jun 2025

FD Technologies revenue rises but loss widens as admin costs mount

(Alliance News) - FD Technologies PLC on Tuesday said revenue increased while its pretax loss widened in the 2025 financial year, as its takeover offe...

FD Technologies accepts GBP570 million offer by Boston's TA Associates
8 May 2025

FD Technologies accepts GBP570 million offer by Boston's TA Associates

(Alliance News) - FD Technologies PLC on Thursday accepted a GBP570 million takeover offer from TA Associates Management LP, a day after talks between...

FD Technologies News

DIRECTOR DEALINGS: First Derivatives Non-Executive Sells 10,000 Shares
11 Feb 2014

DIRECTOR DEALINGS: First Derivatives Non-Executive Sells 10,000 Shares

LONDON (Alliance News) - First Derivatives PLC Tuesday said non-executive Director David Anderson sold 10,000 shares at a price of 1,300 pence per sha...

First Derivatives Opens Singapore Office Amid Asian Expansion
6 Feb 2014

First Derivatives Opens Singapore Office Amid Asian Expansion

LONDON (Alliance News) - First Derivatives PLC Thursday said it has opened its new Singapore office as it looks to build on its expansion into Asia. I...

Alliance Pharma exec offloads 300,000 shares
20 Jan 2014

Alliance Pharma exec offloads 300,000 shares

Speciality drugs firm Alliance Pharma announced Monday that Executive Director Anthony Booley's share in the company was reduced by 300,000 shares aft...

DIRECTOR DEALINGS: First Derivatives Non-Executive Sells 2,500 Shares
20 Jan 2014

DIRECTOR DEALINGS: First Derivatives Non-Executive Sells 2,500 Shares

LONDON (Alliance News) - First Derivatives PLC Monday said Non-Executive Director David Anderson sold 2,500 shares at a price of 1,356 pence per shar...

Tuesday broker round-up UPDATE
17 Dec 2013

Tuesday broker round-up UPDATE

Advanced Medical Solutions: Panmure Gordon downgrades from buy to hold with a target price of 102p. Antofagasta: Canaccord Genuity cuts target price ...

Thursday broker round-up UPDATE
14 Nov 2013

Thursday broker round-up UPDATE

Afren: Goldman Sachs moves target price from 260p to 270p and retains its strong buy recommendation. APR Energy: Citi raises target price from 1250p ...